Beyond Scientific Exchange: How to Elevate MSL Teams from Trusted Experts to Strategic Growth Partners

Author(s): Óscar Mata Peña

For many years, Medical Affairs has been described as the bridge between science and clinical practice. That description is still true—but today, it is no longer sufficient.

The pharmaceutical industry has changed dramatically. Therapies have become increasingly complex. Healthcare systems demand stronger evidence. Patients expect more personalized care. Artificial intelligence is transforming how knowledge is generated and consumed. And commercial organizations are under unprecedented pressure to demonstrate value beyond product promotion. In this environment, the role of the Medical Science Liaison (MSL) must evolve as well.

The best MSL organizations are no longer measured simply by the number of scientific interactions they conduct or the volume of insights they collect. They are becoming strategic partners that actively shape evidence generation, support better clinical decisions, accelerate innovation, and influence business strategy without compromising scientific integrity.

After more than fifteen years working in Medical Affairs, one lesson has become increasingly clear